CXCR4靶向68Ga-五肽抑素PET/CT显像在炎症性肠病中的应用
纳入5例炎症性肠病患者与12例对照行68Ga-五肽抑素PET/CT,内镜证实病灶13/13均显像阳性,病灶段SUVmax中位数3.15高于对照正常肠段1.67(P<0.001),作者认为该显像对评估活动性肠道病变有潜在价值且无需禁食或肠道准备。
要点
- 内镜证实的13个病变段68Ga-五肽抑素PET/CT全部阳性(13/13)。
- 病变段SUVmax中位数3.15(范围1.61-6.26)高于对照正常肠段1.67(1.18-2.29),P<0.001。
- 该显像无需禁食或肠道准备,作者认为耐受性与安全性良好。
核心结论
- 68Ga-五肽抑素PET/CT可能是评估炎症性肠病活动性肠道病变的有潜在价值工具,灵敏度高。
- 该无创方法无需禁食或肠道准备,耐受性与安全性良好。
研究设计与样本
- 纳入5例炎症性肠病患者和12例对照受试者行68Ga-五肽抑素PET/CT检查。
- 记录并比较68Ga-五肽抑素PET/CT显像与内镜所见,分析病变段与对照正常肠道的半定量摄取参数。
主要发现
- 5例患者内镜共检查26个肠段,其中13个肠段显示内镜病变。
- 68Ga-五肽抑素PET/CT在所有内镜证实的病变中均为阳性(13/13)。
- 该显像还显示了因严重狭窄内镜无法到达的小肠和结肠病变,以及伴发的肠系膜淋巴结炎。
- 病变段SUVmax中位数3.15(范围1.61-6.26)高于对照组正常肠道1.67(1.18-2.29),P<0.001。
- 病变段/肝脏SUVmax比值中位数2.20(范围1.13-3.26)高于对照0.85(0.54-1.20),P≤0.001;病变段/血池比值中位数1.66(范围0.94-2.95)高于对照0.67(0.52-1.04),P≤0.001。
临床怎么用
- 作者认为68Ga-五肽抑素PET/CT可作为评估炎症性肠病活动性肠道病变的潜在工具。
- 原文指出该无创方法无需禁食或肠道准备,耐受性与安全性良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the role of CXCR4-targeted 68 Ga-pentixafor PET/CT imaging in inflammatory bowel disease (IBD). METHODS: Five IBD patients and 12 control subjects performing 68 Ga-pentixafor PET/CT examinations were included. 68 Ga-pentixafor PET/CT imaging and endoscopic findings were recorded and compared. The semiquantitative parameters of 68 Ga-pentixafor uptake by the lesion segments in IBD patients and the normal intestines in the control were investigated. RESULTS: Among these 5 IBD patients, endoscopy successfully examined a total of 26 intestinal segments, with 13 segments showing endoscopic lesions. 68 Ga-pentixafor PET/CT was positive in all endoscopy-proven lesions (13/13). Additionally, 68 Ga-pentixafor PET/CT revealed the lesions in small intestines and colons that cannot be reached by endoscopy due to severe stenosis, and mesenteric lymphadenitis accompanied IBD. The SUV max of the lesion segments in IBD patients was significantly higher than that of the normal intestines in the control group (median, 3.15 [range, 1.61-6.26] vs 1.67 [1.18-2.29], P < 0.001). Moreover, the SUV max ratios of the lesion segments/liver or blood pool were higher when compared with the control (2.20 [1.13-3.26] vs 0.85 [0.54-1.20]; 1.66 [0.94-2.95] vs 0.67 [0.52-1.04]; P ≤ 0.001). CONCLUSIONS: 68 Ga-pentixafor PET/CT can be a potentially valuable tool to assess the active intestinal lesions of IBD with high sensitivity. Moreover, this noninvasive approach does not require fasting or bowel preparation, offering good tolerance and safety.
引用
- Chen Y, Yuan H, Tan X, et al. CXCR4-Targeted 68 Ga-Pentixafor PET/CT Imaging in Inflammatory Bowel Disease. Clin Nucl Med. 2024. PMID: 39086048. doi:10.1097/RLU.0000000000005374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。